ZANTAC 300
LOE ApproachingNDAORALTABLET
Approved
Jun 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 300 is an oral tablet containing 300 mg of ranitidine, a histamine H2-receptor antagonist approved in 1983 for treating acid-reflux conditions. The drug reduces gastric acid secretion by blocking H2 receptors on parietal cells. It has been a long-standing, widely-used therapeutic for peptic ulcer disease and gastroesophageal reflux disease (GERD).
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), commercial teams face declining revenue and shrinking field force opportunities; career growth unlikely on this asset.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZANTAC 300 offers limited career growth due to mature lifecycle, generic competition, and declining market share. Roles are primarily maintenance-focused rather than launch or expansion-driven, making this assignment less attractive for ambitious pharma professionals seeking high-impact opportunities.
Brand ManagerField Sales
Worked on ZANTAC 300 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.